Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

Clinical pharmacokinetics; concepts and applications

1989 • 2,266 citations

DNA TOPOISOMERASES

1985 • 1,524 citations

Kinetics of pharmacologic response

1982 • 508 citations

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

1989 • 467 citations

Topoisomerase-targeting antitumor drugs

1989 • 441 citations

Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.

1990 • 427 citations

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

1992 • 363 citations

Effects of CPT‐11 in combination with other anti‐cancer agents in culture

1992 • 226 citations

Clinical Pharmacokinetics of Topotecan

1996 • 182 citations

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

1993 • 174 citations

Nonproductive Rearrangement of DNA Topoisomerase I and II Genes: Correlation With Resistance to Topoisomerase Inhibitors

1989 • 172 citations

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.

1991 • 165 citations

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

1993 • 135 citations

Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.

1990 • 133 citations

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

1992 • 128 citations

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1993 • 123 citations

DNA topoisomerase I and II as targets for rational design of new anticancer drugs

1993 • 121 citations

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1992 • 112 citations

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

1992 • 109 citations

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.

1994 • 97 citations

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1995 • 95 citations

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma

1995 • 82 citations

Characterization of camptothecin-resistant chinese hamster lung cells

1992 • 81 citations

High-Performance Liquid Chromatographic Analysis of the Semisynthetic Epipodophyllotoxins Teniposide and Etoposide Using Electrochemical Detection

1984 • 67 citations

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

1994 • 60 citations

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.

1993 • 60 citations

Isolation and structural confirmation of N -desmethyl topotecan, a metabolite of topotecan

1997 • 42 citations

Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.

1995 • 33 citations

Concepts of synergism and antagonism.

1994 • 24 citations

84 Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)

1995 • 12 citations

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1990 • 12 citations

Principles of Chemotherapy

1993 • 8 citations

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1994 • 4 citations

Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules

1996 • 3 citations